Vaccination with toxoplasma gondii SAG1 protein in a mouse model of congenital toxoplasmosis

La toxoplasmose congénitale est provoquée par la transmission maternofoetale de Toxoplasma gondii, un protozoaire parasite intracellulaire, lors d'une primoinfection au cours de la gestation. Nous avons caractérisé les propriétés vaccinales de la protéine de surface SAG1 de T. gondii dans un modèle de toxoplasmose congénitale chez la souris. La vaccination avec SAG1 avant la gestation réduit de 50% l'infection foetale chez la souris BALB/c (H2d) infectée pendant la gestation, diminue de 82% la parasitémie maternelle et induit une réponse immunitaire maternelle mixte Th1 et Th2 caractérisée par une production accrue d'IFN et d'IL10 et par la production de titres élevés en IgG1 anti-SAG1 et faibles en IgG2a anti-SAG1. Nous avons identifié plusieurs mécanismes effecteurs de la protection vaccinale induite par SAG1, impliquant les anticorps anti-SAG1, les lymphocytes T CD8+ cytotoxiques, une production précoce d'IFN et une activité toxoplasmicide des macrophages.Toxoplasma gondii is an protozoan intracellular parasite. Congenital toxoplasmosis is the result of the parasite crossing the placenta during primary maternel infection. We characterized the efficacy of vaccination with the T. gondii surface SAG1 protein in a mouse model of congenital toxoplasmosis. SAG1 vaccination before gestation reduces the fetal infection by 50% in BALB/c mice (H2d) and this protection is associated with a reduced maternel parasitemia by 82%, and a mixed Th1 and Th2 maternel immune response with an increased production of IFN and IL10 and with an important production of specific anti-SAG1 IgG1 and a lesser production of anti-SAG1 IgG2a. We identified some protective mechanisms including the anti-SAG1 specific antibodies, the cytotoxic CD8+ T lymphocytes, an early production of IFN and a toxoplasmicidal activity mediated by macrophages

Vaccination with toxoplasma gondii SAG1 protein in a mouse model of congenital toxoplasmosis

La toxoplasmose congénitale est provoquée par la transmission maternofoetale de Toxoplasma gondii, un protozoaire parasite intracellulaire, lors d'une primoinfection au cours de la gestation. Nous avons caractérisé les propriétés vaccinales de la protéineToxoplasma gondii is an protozoan intracellular parasite. Congenital toxoplasmosis is the result of the parasite crossing the placenta during primary maternel infection. We characterized the efficacy of vaccination with the T. gondii surface SAG1 protei

Vaccination avec la protéine SAG1 de toxoplasma gondii dans un modèle de toxoplasmose congénitale chez la souris

La toxoplasmose congénitale est provoquée par la transmission maternofoetale de Toxoplasma gondii, un protozoaire parasite intracellulaire, lors d'une primoinfection au cours de la gestation. Nous avons caractérisé les propriétés vaccinales de la protéine de surface SAG1 de T. gondii dans un modèle de toxoplasmose congénitale chez la souris. La vaccination avec SAG1 avant la gestation réduit de 50% l'infection foetale chez la souris BALB/c (H2d) infectée pendant la gestation, diminue de 82% la parasitémie maternelle et induit une réponse immunitaire maternelle mixte Th1 et Th2 caractérisée par une production accrue d'IFN et d'IL10 et par la production de titres élevés en IgG1 anti-SAG1 et faibles en IgG2a anti-SAG1. Nous avons identifié plusieurs mécanismes effecteurs de la protection vaccinale induite par SAG1, impliquant les anticorps anti-SAG1, les lymphocytes T CD8+ cytotoxiques, une production précoce d'IFN et une activité toxoplasmicide des macrophages.Toxoplasma gondii is an protozoan intracellular parasite. Congenital toxoplasmosis is the result of the parasite crossing the placenta during primary maternel infection. We characterized the efficacy of vaccination with the T. gondii surface SAG1 protein in a mouse model of congenital toxoplasmosis. SAG1 vaccination before gestation reduces the fetal infection by 50% in BALB/c mice (H2d) and this protection is associated with a reduced maternel parasitemia by 82%, and a mixed Th1 and Th2 maternel immune response with an increased production of IFN and IL10 and with an important production of specific anti-SAG1 IgG1 and a lesser production of anti-SAG1 IgG2a. We identified some protective mechanisms including the anti-SAG1 specific antibodies, the cytotoxic CD8+ T lymphocytes, an early production of IFN and a toxoplasmicidal activity mediated by macrophages.STRASBOURG-Sc. et Techniques (674822102) / SudocSudocFranceF

Détection du galactomannane aspergillaire dans l'expectoration (mise au point et performances du test dans le diagnostic des aspergilloses invasives)

STRASBOURG-Medecine (674822101) / SudocSudocFranceF

Voriconazole ( évaluation de la sensibilité des levures du genre Candida et comparaison des techniques de détermination des concentrations minimales inhibitrices E-test® et Biomic®)

STRASBOURG-Medecine (674822101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Identification des levures par la technique Maldi-Tof comparaison du Biflex III-Biotyper et de l'Axima-Saramis / Caroline Lohmann

STRASBOURG ILLKIRCH-Pharmacie (672182101) / SudocSudocFranceF

Yarrowia lipolytica causes sporadic cases and local outbreaks of infections and colonisation

Background Yarrowia lipolytica belongs to the normal human microbiota but is also found in substrates with high contents in lipids and used in biotechnological processes. It is sometimes reported as human pathogen and especially in catheter-related candidaemia.Objectives Two apparently grouped cases of infections and/or contamination were reported involving 3 and 9 patients, respectively, in two hospitals. The goal of this study was to design a molecular tool to study the genetic diversity of Y lipolytica and confirm or not the common source of contamination during these grouped cases.Methods Given that there is no genotyping method, we used genomic markers assessed on environmental isolates to determine intra-species relationship. We selected five highly polymorphic intergenic regions, totalling more than 3200 bp and sequenced them for clinical (n = 20) and environmental (n = 14) isolates. Antifungal susceptibility was determined by EUCAST broth microdilution method.Results Multiple alignment of the five sequences revealed divergence of 0%-5.8% between isolates as compared to approximately 0.2%-0.25% after alignment of whole genomes, suggesting their potential usefulness to establish genetic relatedness. The analysis showed the multiple origins of the isolates. It uncovered two grouped case of fungaemia involving 3 and 2 patients, respectively. It also revealed several unrelated sporadic cases despite their temporal relationship and one probable laboratory contamination by a common yet uncovered source, explaining several consecutive positive cultures without infection. All isolates had high minimal inhibitory concentration (MIC) for flucytosine, the majority (14/34) was susceptible to fluconazole, and all to the other antifungal agents tested

First case of Arthrographis kalrae fungemia in a patient with cystic fibrosis

Arthrographis kalrae is a hyalin fungus. It is a saprophyte of the environment, mainly found in soil and compost. In recent years, cases of opportunistic infections attributed to this pathogen have been described. Our patient was a 19-year-old woman with cystic fibrosis. She presented a bacterial and fungal pulmonary colonization with Aspergillus fumigatus and Arthrographis. kalrae. After her lung transplantation, she developed an A. kalrae fungemia, treated with caspofungin 50 mg/day associated to liposomal amphotericin B i.v. 3 mg/kg/day. The patient died 8 months after her transplantation as the result of a bacterial septic shock